Home › Breast Cancer › NCT06127979
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
Differential Changes in Ki67 Between Carriers and Noncarriers of BRCA2 Mutations With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer Treated With Preoperative Endocrine Therapy
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: * Postmenopausal women aged ≥18 years with biopsy-proven stage I-III invasive breast cancer that is ER+/HER2- * Scheduled to undergo upfront surgery * Eligible for genetic testing in accordance with National Comprehensive Cancer Network guidelines(BRCA2 arm only) Exclusion Criteria: * History of breast cancer * Receipt of ET for risk reduction in the previous 3 months * Stage IV disease at presentation * Scheduled to undergo neoadjuvant systemic chemotherapy * Pregnant
About the study
The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery. Participants will receive the endocrine therapy before their surgery. The researchers will look at how changes in Ki67 expression compare between participants who are carriers of the BRCA2 mutation and participants who are noncarriers of the BRCA2 mutation.
What is being tested
- core needle biopsy (procedure)
- blood draw (other)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 42 · Started: Aug 30, 2024
Contact the study team
- Minna Lee, MD · Phone: 646-888-6898
- Komal Jhaveri, MD · Phone: 646-888-5157
Official record on ClinicalTrials.gov — NCT06127979
Locations in the U.S.
| New York | Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.